Álvaro Pinto Marín

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study

Begoña Pérez‐Valderrama, Jóse Ángel Arranz Arija, Ángel Rodríguez Sánchez et al. · Annals of Oncology · 2015 · 37 citations · Full text

Medicine, Oncology, Pharmacology +15

Comparison of Prognostic Gene Profiles Using qRT-PCR in Paraffin Samples: A Retrospective Study in Patients with Early Breast Cancer

Enrique Espinosa, Iker Sánchez‐Navarro, Angelo Gámez‐Pozo et al. · PLoS ONE · 2009 · 18 citations · Full text

Medicine, Molecular Biology, Oncology +17

LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy

Begoña P. Valderrama, D. Castellano Gauna, Álvaro Pinto Marín et al. · Annals of Oncology · 2020 · 10 citations

Medicine, Oncology, Pharmacology +14